Exonate is a privately held, early stage, biotech, company spun out of the University of Nottingham
that is focused on Vascular Endothelial Growth Factor (VEGF). The Company has grown
significantly in the last year as it welcomes investment and input from an increasing Global
It aspires to successfully deliver medicines in areas of unmet need, by targeting diseases through
regulation of VEGF isoforms/variants that are both protective and disease promoting. Exonate’s
lead program is focused on wet Age-Related Macular Degeneration, (wet AMD), which is the
leading cause of vision loss in people aged 60 and older. The Company is founded on scientific
excellence with strong links to Prof. David Bates and his lab at Nottingham University
specialising in the biology and biochemical pathways of VEGF splice variants. In addition Exonate
has formed academic collaborations with the university of New South Wales (Australia) and
Professor Jonathan Morris.
Exonate have developed small molecules that inhibit production of pro-angiogenic VEGF through
selective inhibition of serine/threonine-protein kinase 1 (SRPK1)-mediated VEGF splicing. These
inhibitors have already demonstrated superior efficacy as topical agents in preclinical models of wet
Exonate is led by an experienced, international management team that has worked together
previously, successfully raising capital for start-ups and early stage companies over many years.
Exonate’s management has cross-disciplinary experience in medicine, finance, drug development
and the pharmaceutical and biotech industries. CEO Catherine Beech, has over 25 years
biotech/pharma experience including 12 years in big pharma leading development programs in
cardiovascular, Parkinson’s disease and HIV.
Nottingham Angels and Fusion IP make first investment in University spin-out business, Exonate
Dr Chris Torrance joins the Exonate Board of Directors Prof Pete Adamson and Prof Usha Chakravarthy join the Exonate CABMeet our Team
Exonate closes 2nd successful funding round
Exonate closes 3rd successful funding round – to develop eye drops treatment for wet age-related macular degeneration (wet AMD)
Exonate turns 3! Andy Baxter joins as Head of Product DevelopmentMeet Andy Baxter
Exonate receives Wellcome Trust funding to develop eye drop treatment for wet age-related macular degeneration (wet AMD)See our Investors
Exonate is the ‘One to Watch’ in the Best Investment in Life Sciences
Exonate announces the formation of ophthalmology Clinical Advisory Board (“Exonate” or the “Company”)Meet the Team
Exonate nominates compounds for clinical development
Exonate raises £1.5 million during successful fourth financing roundSee our Investors
Exonate recognised in Top 21 companies to watch award from CofinitiveSee our Updates
Our strength is scientific expertise with cross-disciplinary experience in medicine and drug development, alongside a track record of raising capital for early stage companies. Our work is supported by highly respected Clinical and Scientific Advisory boards made up of leading international Key Opinion Leaders (KOLs) from the ophthalmology industry.
As an early stage biotechnology company, we are a strong, well-funded International business, supported by a highly-respected Blue-chip investors.